Date: 2014-03-07
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France - Austria) Emergent BioSolutions (USA - MD)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease:
Details: * On March 7, 2014, Valneva has announced that it has signed a new research license agreement and transferred an existing commercial agreement to Emergent BioSolutions, to develop new vaccines using Valneva’s EB66® cell line. The agreements will grant Emergent and its affiliates the rights to research and commercialize new and existing vaccine candidates using Valneva’s EB66® technology.The commercial license, which was initially granted to the Oxford-Emergent Tuberculosis Consortium (OETC) for the development of Tuberculosis vaccines, will be transferred to Emergent. To date, Valneva has more than 35 license agreements with the world’s largest pharmaceutical companies for the use of its EB66® vaccine production platform in both human and animal health vaccines.
Financial terms: Financial terms of the agreements were not disclosed but do include upfront and annual maintenance payments. If successful, product candidates from these agreements may lead to additional cash payments for achieved milestones along with future royalties on net sales.
Latest news:
